{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:32:58Z","timestamp":1782977578060,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Children&apos;s Gaucher Research Fund"},{"name":"Erwin Schr\u00f6dinger Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Almost all attempts to date at gene therapy approaches for monogenetic disease have used the amino acid sequences of the natural protein. In the current study, we use a designed, thermostable form of glucocerebrosidase (GCase), the enzyme defective in Gaucher disease (GD), to attempt to alleviate neurological symptoms in a GD mouse that models type 3 disease, i.e. the chronic neuronopathic juvenile subtype. Upon injection of an AAVrh10 (adeno-associated virus, serotype rh10) vector containing the designed GCase (dGCase) into the left lateral ventricle of\n                    <jats:italic>Gba<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>;Gba<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>tg<\/jats:italic>\n                    <\/jats:sup>\n                    mice, a significant improvement in body weight and life-span was observed, compared to injection of the same mouse with the wild type enzyme (wtGCase). Moreover, a reduction in levels of glucosylceramide (GlcCer), and an increase in levels of GCase activity were seen in the right hemisphere of\n                    <jats:italic>Gba<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>;Gba<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>tg<\/jats:italic>\n                    <\/jats:sup>\n                    mice, concomitantly with a significant improvement in motor function, reduction of neuroinflammation and a reduction in mRNA levels of various genes shown previously to be elevated in the brain of mouse models of neurological forms of GD. Together, these data pave the way for the possible use of modified proteins in gene therapy for lysosomal storage diseases and other monogenetic disorders.\n                  <\/jats:p>","DOI":"10.1038\/s41434-024-00476-8","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T09:02:16Z","timestamp":1723712536000},"page":"439-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of an AAV vector encoding a thermostable form of glucocerebrosidase in alleviating symptoms in a Gaucher disease mouse model"],"prefix":"10.1038","volume":"31","author":[{"given":"Ivan","family":"Milenkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Blumenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Hochfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviya","family":"Azulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal E.","family":"Biton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirie","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-412X","authenticated-orcid":false,"given":"Roni","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tsoory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammar","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarel J.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0013-0115","authenticated-orcid":false,"given":"Anthony H.","family":"Futerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"476_CR1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrm1423","volume":"5","author":"AH Futerman","year":"2004","unstructured":"Futerman AH, Meer G, van. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol. 2004;5:554\u201365.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"476_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1064924","volume":"14","author":"J Kido","year":"2023","unstructured":"Kido J, Sugawara K, Nakamura K. Gene therapy for lysosomal storage diseases: Current clinical trial prospects. Front Genet. 2023;14:1064924.","journal-title":"Front Genet"},{"key":"476_CR3","doi-asserted-by":"publisher","unstructured":"Siebert M, Sidransky E, Westbroek W. Glucocerebrosidase is shaking up the synucleinopathies. Brain 2014. https:\/\/doi.org\/10.1093\/brain\/awu002.","DOI":"10.1093\/brain\/awu002"},{"key":"476_CR4","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1038\/537S160a","volume":"537","author":"AH Futerman","year":"2016","unstructured":"Futerman AH, Hardy J. Perspective: Finding common ground. Nature. 2016;537:S160\u20131.","journal-title":"Nature"},{"key":"476_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/brain\/awac379","volume":"146","author":"R Schiffmann","year":"2022","unstructured":"Schiffmann R, Cox TM, Dedieu J-F, Gaemers SJM, Hennermann JB, Ida H, et al. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain. 2022;146:461\u201374.","journal-title":"Brain"},{"key":"476_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/genes15030364","volume":"15","author":"A Kulkarni","year":"2024","unstructured":"Kulkarni A, Chen T, Sidransky E, Han T-U. Advancements in Viral Gene Therapy for Gaucher Disease. Genes. 2024;15:364.","journal-title":"Genes"},{"key":"476_CR7","first-page":"1","volume":"46","author":"G Massaro","year":"2018","unstructured":"Massaro G, Mattar CNZ, Wong AMS, Sirka E, Buckley SMK, Herbert BR, et al. Fetal gene therapy for neurodegenerative disease of infants. Nat Med. 2018;46:1\u201312.","journal-title":"Nat Med"},{"key":"476_CR8","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1111\/febs.16758","volume":"290","author":"S Pokorna","year":"2023","unstructured":"Pokorna S, Khersonsky O, Lipsh\u2010Sokolik R, Goldenzweig A, Nielsen R, Ashani Y, et al. Design of a stable human acid\u2010\u03b2\u2010glucosidase: towards improved Gaucher disease therapy and mutation classification. FEBS J. 2023;290:3383\u201399.","journal-title":"FEBS J"},{"key":"476_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.molcel.2016.06.012","volume":"63","author":"A Goldenzweig","year":"2016","unstructured":"Goldenzweig A, Goldsmith M, Hill SE, Gertman O, Laurino P, Ashani Y, et al. Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability. Mol Cell. 2016;63:337\u201346.","journal-title":"Mol Cell"},{"key":"476_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1146\/annurev-biochem-062917-012102","volume":"87","author":"A Goldenzweig","year":"2018","unstructured":"Goldenzweig A, Fleishman S. Principles of Protein Stability and Their Application in Computational Design. Annu Rev Biochem. 2018;87:105\u201329.","journal-title":"Annu Rev Biochem"},{"key":"476_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101939","volume":"197","author":"Y Pewzner-Jung","year":"2020","unstructured":"Pewzner-Jung Y, Joseph T, Blumenreich S, Vardi A, Ferreira NS, Cho SM, et al. Brain pathology and cerebellar purkinje cell loss in a mouse model of chronic neuronopathic Gaucher disease. Prog Neurobiol. 2020;197:101939.","journal-title":"Prog Neurobiol"},{"key":"476_CR12","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/mds.23774","volume":"26","author":"T Shachar","year":"2011","unstructured":"Shachar T, Bianco CL, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and Parkinson\u2019s disease: Gaucher disease and beyond. Mov Disord. 2011;26:1593\u2013604.","journal-title":"Mov Disord"},{"key":"476_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2144\/00291bm09","volume":"29","author":"GE Truett","year":"2000","unstructured":"Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML. Preparation of PCR-Quality Mouse Genomic DNA with Hot Sodium Hydroxide and Tris (HotSHOT). BioTechniques. 2000;29:52\u201354.","journal-title":"BioTechniques"},{"key":"476_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/hum.2008.155","volume":"20","author":"C Ciron","year":"2009","unstructured":"Ciron C, Cressant A, Roux F, Raoul S, Cherel Y, Hantraye P, et al. Human \u03b1-Iduronidase Gene Transfer Mediated by Adeno-Associated Virus Types 1, 2, and 5 in the Brain of Nonhuman Primates: Vector Diffusion and Biodistribution. Hum Gene Ther. 2009;20:350\u201360.","journal-title":"Hum Gene Ther"},{"key":"476_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113168","volume":"42","author":"RB-T Perry","year":"2023","unstructured":"Perry RB-T, Tsoory M, Tolmasov M, Ulitsky I. Silc1 long noncoding RNA is an immediate-early gene promoting efficient memory formation. Cell Rep. 2023;42:113168.","journal-title":"Cell Rep"},{"key":"476_CR16","doi-asserted-by":"crossref","unstructured":"Kim JL, Ben-Dor S, Rosenfeld-Gur E, Futerman AH. A novel C-terminal DxRSDxE motif in ceramide synthases involved in dimer formation. J Biol Chem. 2022;298:101517.","DOI":"10.1016\/j.jbc.2021.101517"},{"key":"476_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/bj3030377","volume":"303","author":"I Meivar-Levy","year":"1994","unstructured":"Meivar-Levy I, Horowitz M, Futerman AH. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Biochem J. 1994;303:377\u201382.","journal-title":"Biochem J"},{"key":"476_CR18","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1371\/journal.pone.0004792","volume":"4","author":"D Aviezer","year":"2009","unstructured":"Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, et al. A plant-derived recombinant human glucocerebrosidase enzyme\u2013a preclinical and phase I investigation. PLoS ONE. 2009;4:e4792.","journal-title":"PLoS ONE"},{"key":"476_CR19","doi-asserted-by":"publisher","first-page":"8.12.1","DOI":"10.1002\/0471142301.ns0812s15","volume":"15","author":"RJ Carter","year":"2001","unstructured":"Carter RJ, Morton J, Dunnett SB. Motor Coordination and Balance in Rodents. Curr Protoc Neurosci. 2001;15:8.12.1\u20138.12.14.","journal-title":"Curr Protoc Neurosci"},{"key":"476_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1113\/JP280434","volume":"599","author":"A Mett","year":"2021","unstructured":"Mett A, Karbat I, Tsoory M, Fine S, Iwanir S, Reuveny E. Reduced activity of GIRK1\u2010containing heterotetramers is sufficient to affect neuronal functions, including synaptic plasticity and spatial learning and memory. J Physiol. 2021;599:521\u201345.","journal-title":"J Physiol"},{"key":"476_CR21","unstructured":"Futerman AH, Zimran A. Gaucher disease. CRC Press, Taylor and Francis Group."},{"key":"476_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.brainres.2009.10.032","volume":"1308","author":"V Dror","year":"2010","unstructured":"Dror V, Eliash S, Rehavi M, Assaf Y, Biton IE, Fattal-Valevski A. Neurodegeneration in thiamine deficient rats\u2014A longitudinal MRI study. Brain Res. 2010;1308:176\u201384.","journal-title":"Brain Res"},{"key":"476_CR23","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1242\/dmm.008185","volume":"4","author":"T Farfel-Becker","year":"2011","unstructured":"Farfel-Becker T, Vitner EB, Futerman AH. Animal models for Gaucher disease research. Dis models Mech. 2011;4:746\u201352.","journal-title":"Dis models Mech"},{"key":"476_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.4751","volume":"239","author":"A Vardi","year":"2016","unstructured":"Vardi A, Zigdon H, Meshcheriakova A, Klein AD, Yaacobi C, Eilam R, et al. Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. J Pathol. 2016;239:496\u2013509.","journal-title":"J Pathol"},{"key":"476_CR25","doi-asserted-by":"publisher","first-page":"e0120194","DOI":"10.1371\/journal.pone.0120194","volume":"10","author":"H Zigdon","year":"2015","unstructured":"Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiffmann R, Futerman AH. Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease. PLoS ONE. 2015;10:e0120194.","journal-title":"PLoS ONE"},{"key":"476_CR26","doi-asserted-by":"publisher","unstructured":"Blumenreich S, Yaacobi C, Vardi A, Barav OB, Vitner EB, Park H, et al. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease. J Neurochem 2020. https:\/\/doi.org\/10.1111\/jnc.15136.","DOI":"10.1111\/jnc.15136"},{"key":"476_CR27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/mt.2015.122","volume":"23","author":"N-C Lee","year":"2015","unstructured":"Lee N-C, Muramatsu S-I, Chien Y-H, Liu W-S, Wang W-H, Cheng C-H, et al. Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency. Mol Ther. 2015;23:1572\u201381.","journal-title":"Mol Ther"},{"key":"476_CR28","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/hmg\/ddz317","volume":"29","author":"G Massaro","year":"2020","unstructured":"Massaro G, Hughes MP, Whaler SM, Wallom K-L, Priestman DA, Platt FM, et al. Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes. Hum Mol Genet. 2020;29:1933\u201349.","journal-title":"Hum Mol Genet"},{"key":"476_CR29","doi-asserted-by":"publisher","first-page":"17483","DOI":"10.1073\/pnas.0708086104","volume":"104","author":"IB Enquist","year":"2007","unstructured":"Enquist IB, Bianco CL, Ooka A, Nilsson E, Mansson JE, Ehinger M, et al. Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci USA. 2007;104:17483\u20138.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00476-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T05:15:01Z","timestamp":1726204501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00476-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":29,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00476-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4210702\/v1","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SJF is a named inventor on designed proteins and methods described in the manuscript and consults on protein design.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}